CERC

Cerecor's Crohn's Disease Candidate Shows Encouraging Response In Pretreated Patients

Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets

Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients

Cerecor's investigational COVID-19 therapy gets Fast Track designation from the FDA

A Small Biotech Stock That Has All The Right Ingredients for a Big 2021 Breakout

Cerecor Inks New Global License Agreement With Kyowa Kirin For CERC-002

Cerecor Reports 2020 Financial Results and Provides Business Updates